GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Androgen Receptor Reactivation after Androgen Deprivation Therapy - Highlight
SAN FRANCISCO, CA (UroToday.com) - Dr. Balk discussed the modest clinical benefit of AR antagonists in addition to androgen-deprivation therapy (ADT). However, AR is expressed at levels that are comparable to primary CaP, although the expression may not be heterogeneous.
 | Written by Christopher P. Evans, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |